Possible vaccine strategies for EBV: unanswered questions
Potential vaccines may . | Vaccine strategy/unanswered questions . |
|---|---|
| Prevent infection entirely | Give vaccine in infancy |
| Does vaccine induce sterile immunity? | |
| Prevent symptomatic primary infection (IM) | Give vaccine to all students who leave school |
| Should vaccine be given only to EBV seronegatives? | |
| Does vaccine prevent death in XLPS? | |
| Does vaccine prevent PTLD in EBV-negative transplant recipients? | |
| Prevent EBV-associated tumors | Does this require sterile immunity? |
| Does this require neutralizing antibody and/or cytotoxic T-cell activity? | |
| Can prevention be achieved with gp350 vaccine? |
Potential vaccines may . | Vaccine strategy/unanswered questions . |
|---|---|
| Prevent infection entirely | Give vaccine in infancy |
| Does vaccine induce sterile immunity? | |
| Prevent symptomatic primary infection (IM) | Give vaccine to all students who leave school |
| Should vaccine be given only to EBV seronegatives? | |
| Does vaccine prevent death in XLPS? | |
| Does vaccine prevent PTLD in EBV-negative transplant recipients? | |
| Prevent EBV-associated tumors | Does this require sterile immunity? |
| Does this require neutralizing antibody and/or cytotoxic T-cell activity? | |
| Can prevention be achieved with gp350 vaccine? |
PTLD indicates posttransplantation lymphoproliferative disease; XLPS, X-linked lymphoproliferative syndrome.